Completed PHASE3 INTERVENTIONAL NCT00000427

Effects of Parathyroid Hormone in Men With Osteoporosis

Anabolic Actions of Parathyroid Hormone in Osteoporotic Men

Sponsor: Massachusetts General Hospital

Interventions Alendronate Parathyroid hormone

Updated 6 times since 2017 Last updated: Dec 6, 2013 Started: Sep 30, 1999 Primary completion: Oct 31, 2005 Completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Osteoporosis, this trial is completed. The trial is conducted by Massachusetts General Hospital and has accumulated 6 data snapshots since 1999. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States